[go: up one dir, main page]

MX2017000676A - Oritavancina de alta pureza y metodo para producir la misma. - Google Patents

Oritavancina de alta pureza y metodo para producir la misma.

Info

Publication number
MX2017000676A
MX2017000676A MX2017000676A MX2017000676A MX2017000676A MX 2017000676 A MX2017000676 A MX 2017000676A MX 2017000676 A MX2017000676 A MX 2017000676A MX 2017000676 A MX2017000676 A MX 2017000676A MX 2017000676 A MX2017000676 A MX 2017000676A
Authority
MX
Mexico
Prior art keywords
high purity
oritavancina
produce
same
oritavacin
Prior art date
Application number
MX2017000676A
Other languages
English (en)
Other versions
MX385925B (es
Inventor
Rafai Far Adel
Krishna Gopal
Ding Min
R Chemburkar Sanjay
M Knable Carl
J Pruyne Julie
M Reamer Douglas
P Petzel James
Original Assignee
The Medicines Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Medicines Co filed Critical The Medicines Co
Publication of MX2017000676A publication Critical patent/MX2017000676A/es
Publication of MX385925B publication Critical patent/MX385925B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describen preparaciones de sustancia fármaco de oritavacina que tienen alta pureza, junto con composiciones farmacéuticas que comprenden tales preparaciones de sustancia fármaco de oritavacina, y productos de fármaco o formas de dosificación que comprenden tales composiciones farmacéuticas.
MX2017000676A 2014-07-17 2015-07-16 Oritavancina de alta pureza y método para producir la misma. MX385925B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462025737P 2014-07-17 2014-07-17
PCT/US2015/040736 WO2016011245A1 (en) 2014-07-17 2015-07-16 High purity oritavancin and method of producing same

Publications (2)

Publication Number Publication Date
MX2017000676A true MX2017000676A (es) 2018-01-11
MX385925B MX385925B (es) 2025-03-18

Family

ID=55073658

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000676A MX385925B (es) 2014-07-17 2015-07-16 Oritavancina de alta pureza y método para producir la misma.

Country Status (16)

Country Link
US (3) US9649352B2 (es)
EP (2) EP4509178A3 (es)
JP (1) JP6712991B2 (es)
CN (1) CN107206050A (es)
AU (1) AU2015289602B2 (es)
BR (1) BR112017000898A2 (es)
CA (1) CA2955256C (es)
EA (1) EA201700019A1 (es)
ES (1) ES3009067T3 (es)
HK (1) HK1244447A1 (es)
HR (1) HRP20250212T1 (es)
HU (1) HUE070928T2 (es)
MX (1) MX385925B (es)
NZ (1) NZ728401A (es)
PL (1) PL3169345T3 (es)
WO (1) WO2016011245A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107793472A (zh) * 2016-09-07 2018-03-13 浙江海正药业股份有限公司 奥利万星二磷酸盐的晶型及其制备方法和用途
CN106928323B (zh) * 2017-03-02 2021-08-20 重庆乾泰生物医药有限公司 一种高纯度奥利万星关键中间体a82846b的制备方法
CN109053864B (zh) * 2018-07-10 2021-08-24 丽珠集团新北江制药股份有限公司 一种制备奥利万星的方法
CN109053865B (zh) * 2018-07-20 2021-04-13 丽珠集团新北江制药股份有限公司 一种羧基保护制备奥利万星的方法
CN109811024B (zh) * 2019-04-02 2021-08-06 博瑞生物医药泰兴市有限公司 发酵制备奥利万星中间体的方法
CN109811023B (zh) * 2019-04-02 2021-08-06 博瑞生物医药泰兴市有限公司 A82846b的发酵制备方法
CN109762860B (zh) * 2019-04-02 2021-10-01 博瑞生物医药泰兴市有限公司 一种碱降解液
CN110824079B (zh) * 2019-11-27 2021-04-13 苏州赛分科技有限公司 特拉万星的纯化方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG18377A (en) * 1986-09-19 1993-04-30 Lilly Co Eli Process for preparing glycopeptide antibiotics
US4845194A (en) 1987-02-27 1989-07-04 Eli Lilly And Company Glycopeptide recovery process
NZ236393A (en) * 1989-12-13 1992-05-26 Lilly Co Eli N-alkylated glycopeptide derivatives prepared from antibiotics a82846 series and pa-42867-a; pharmaceutical compositions
US5840684A (en) * 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
NZ270387A (en) * 1994-01-28 1996-11-26 Lilly Co Eli Glycopeptide antibiotic, its production and compositions thereof
US5952466A (en) 1997-11-12 1999-09-14 Eli Lilly And Company Reductive alkylation of glycopeptide antibiotics
ID18900A (id) * 1996-11-21 1998-05-20 Lilly Co Eli Alkilasi menurun dari gliko peptida anti biotik
US5939382A (en) * 1996-11-21 1999-08-17 Eli Lilly And Company Reducing agent for reductive alkylation of glycopeptide antibiotics
CA2330621A1 (en) * 1998-05-05 1999-11-11 Eli Lilly And Company Purification of carboxaldehyde
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
US7119061B2 (en) 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
PT1565201T (pt) * 2002-11-18 2019-02-05 Vicuron Pharmaceuticals Llc Métodos de administração de dalbavancina para o tratamento de infeções bacterianas
ES2884673T3 (es) 2008-04-08 2021-12-10 Melinta Therapeutics Inc Oritavancina para inhibir y tratar biopelículas
DK2337575T3 (en) * 2008-08-30 2016-05-23 Medicines Co A method of treatment with single doses of oritavancin
US9682061B2 (en) 2009-04-28 2017-06-20 The Medicines Company Methods of treating bacterial infections using oritavancin
WO2011019839A2 (en) 2009-08-12 2011-02-17 The Medicines Company Glycopeptide and lipoglycopeptide antibiotics with improved solubility

Also Published As

Publication number Publication date
AU2015289602A1 (en) 2017-02-09
AU2015289602B2 (en) 2020-06-25
MX385925B (es) 2025-03-18
EP3169345A4 (en) 2018-01-17
EP3169345A1 (en) 2017-05-24
WO2016011245A1 (en) 2016-01-21
EA201700019A1 (ru) 2017-07-31
EP3169345B1 (en) 2025-01-29
US20160015772A1 (en) 2016-01-21
US10328118B2 (en) 2019-06-25
HK1244447A1 (zh) 2018-08-10
CA2955256C (en) 2023-02-14
HRP20250212T1 (hr) 2025-04-11
US9649352B2 (en) 2017-05-16
EP3169345C0 (en) 2025-01-29
BR112017000898A2 (pt) 2017-11-21
NZ728401A (en) 2020-08-28
JP6712991B2 (ja) 2020-06-24
HUE070928T2 (hu) 2025-07-28
US20170157206A1 (en) 2017-06-08
EP4509178A3 (en) 2025-06-25
EP4509178A2 (en) 2025-02-19
CA2955256A1 (en) 2016-01-21
US20190290723A1 (en) 2019-09-26
CN107206050A (zh) 2017-09-26
PL3169345T3 (pl) 2025-04-07
US10864249B2 (en) 2020-12-15
JP2017521443A (ja) 2017-08-03
ES3009067T3 (en) 2025-03-25

Similar Documents

Publication Publication Date Title
MX2017000676A (es) Oritavancina de alta pureza y metodo para producir la misma.
MX390064B (es) Formas cristalinas de mononucleotido de beta-nicotinamida.
MX378273B (es) Compuestos activos hacia bromodominios.
IL253719A0 (en) Pharmaceutical compositions for combination therapy
HRP20181534T1 (hr) Novi spojevi kao inhibitori histonske deacetilaze 6 i farmaceutski pripravci koji ih sadrže
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
IL246837B (en) Antibodies, pharmaceutical compositions and uses thereof
CO2017002472A2 (es) Formulación de acetato de abiraterona
CO2019008103A2 (es) Composiciones farmacéuticas para terapia de combinación
MX2018002318A (es) Proceso mejorado para producir fucoxantina y/o polisacaridos de microalgas.
BR112017015159A2 (pt) preparação e uso de produtos plaquetários
BR112015023523B8 (pt) Composições farmacêuticas e recipiente de forma de dosagem única
MX389178B (es) Formulacion de proporcion fija de insulina glargina/lixisenatida.
MX391152B (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas.
IL248785B (en) Antecedents of ]-n5,1-dimethyl3--oxo-(3,2-dihydro-h1-pyrazol-4-yl)]-methyl-isoxazole-3-carboxamide and pharmaceutical preparations including these antecedents
CL2019000563S1 (es) Envase y dispendio de medicamentos. (divisional solicitud 201800718)
MX389026B (es) Una composicion farmaceutica y el uso de la misma.
CY1121105T1 (el) Φαρμακοτεχνικη μορφη αταζαναβιρης και κομπισιστατης για θεραπεια hiv
HUE059630T2 (hu) Nátrium-fenil-butirátot tartalmazó, kellemes ízû készítmények és alkalmazásaik
EP3285758A4 (en) Co-crystal composition and its pharmaceutical use
EA201791716A1 (ru) Фармацевтический состав
EP3383371C0 (en) PHARMACEUTICAL FORMULATION
IL272284A (en) Thiazolopyridine derivatives, their preparation and pharmaceutical compositions containing them
BR112016012002A2 (pt) Vitanolídeos úteis para o tratamento de doenças neurodegenerativas
HUE057871T2 (hu) Gyógyászati hatóanyagokat tartalmazó hialuronán konjugátumok, eljárások és kompozíciók